Gwak Ho-Shin, Park Myung-Jin, Park In-Chul, Woo Sang Hyeok, Jin Hyeon-Ok, Rhee Chang Hun, Jung Hee-Won
Neuro-Oncology Clinic, National Cancer Center, Goyang;
J Neurosurg. 2014 Dec;121(6):1483-91. doi: 10.3171/2014.8.JNS131991. Epub 2014 Oct 10.
Local invasiveness of malignant glioma is a major reason for the failure of current treatments including surgery and radiation therapy. Tetraarsenic oxide (As4O6 [TAO]) is a trivalent arsenic compound that has potential anticancer and antiangiogenic effects in selected cancer cell lines at a lower concentration than arsenic trioxide (As2O3 [ATO]), which has been more widely tested in vitro and in vivo. The authors tried to determine the cytotoxic concentration of TAO in malignant glioma cell lines and whether TAO would show anti-invasive effects under conditions independent of cell death or apoptosis.
The human phosphatase and tensin homolog (PTEN)-deficient malignant glioma cell lines U87MG, U251MG, and U373MG together with PTEN-functional LN428 were cultured with a range of micromolar concentrations of TAO. The invasiveness of the glioma cell lines was analyzed. The effect of TAO on matrix metalloproteinase (MMP) secretion and membrane type 1 (MT1)-MMP expression was measured using gelatin zymography and Western blot, respectively. Akt, or protein kinase B, activity, which is a downstream effector of PTEN, was assessed with a kinase assay using glycogen synthesis kinase-3β (GSK-3β) as a substrate and Western blotting of phosphorylated Akt.
Tetraarsenic oxide inhibited 50% of glioma cell proliferation at 6.3-12.2 μM. Subsequent experiments were performed under the same TAO concentrations and exposure times, avoiding the direct tumoricidal effect of TAO, which was confirmed with apoptosis markers. An invasion assay revealed a dose-dependent decrease in invasiveness under the influence of TAO. Both the gelatinolytic activity of MMP-2 and MT1-MMP expression decreased in a dose-dependent manner in all cell lines, which was in accordance with the invasion assay results. The TAO decreased kinase activity of Akt on GSK-3β assay and inhibited Akt phosphorylation in a dose-dependent manner in all cell lines regardless of their PTEN status.
These results showed that TAO effectively inhibits proliferation of glioblastoma cell lines and also exerts an anti-invasive effect via decreased MMP-2 secretion, decreased MT1-MMP expression, and the inhibition of Akt phosphorylation under conditions devoid of cytotoxicity. Further investigations using an in vivo model are needed to evaluate the potential role of TAO as an anti-invasive agent.
恶性胶质瘤的局部侵袭性是包括手术和放射治疗在内的当前治疗失败的主要原因。四氧化四砷(As4O6 [TAO])是一种三价砷化合物,在某些癌细胞系中,其具有潜在的抗癌和抗血管生成作用,且浓度低于三氧化二砷(As2O3 [ATO]),后者已在体外和体内进行了更广泛的测试。作者试图确定TAO在恶性胶质瘤细胞系中的细胞毒性浓度,以及TAO在独立于细胞死亡或凋亡的条件下是否会显示出抗侵袭作用。
将人磷酸酶及张力蛋白同源物(PTEN)缺陷的恶性胶质瘤细胞系U87MG、U251MG和U373MG以及PTEN功能正常的LN428与一系列微摩尔浓度的TAO一起培养。分析胶质瘤细胞系的侵袭性。分别使用明胶酶谱法和蛋白质印迹法测量TAO对基质金属蛋白酶(MMP)分泌和膜型1(MT1)-MMP表达的影响。以糖原合成激酶-3β(GSK-3β)为底物,通过激酶测定法和磷酸化Akt的蛋白质印迹法评估PTEN的下游效应器Akt或蛋白激酶B的活性。
四氧化四砷在6.3 - 12.2 μM时抑制50%的胶质瘤细胞增殖。随后在相同的TAO浓度和暴露时间下进行实验,避免TAO的直接杀肿瘤作用,这通过凋亡标志物得到证实。侵袭试验显示在TAO的影响下侵袭性呈剂量依赖性降低。在所有细胞系中,MMP-2的明胶酶活性和MT1-MMP表达均呈剂量依赖性降低,这与侵袭试验结果一致。在GSK-3β测定中,TAO降低了Akt的激酶活性,并且在所有细胞系中,无论其PTEN状态如何,均以剂量依赖性方式抑制Akt磷酸化。
这些结果表明,TAO有效抑制胶质母细胞瘤细胞系的增殖,并且在无细胞毒性的条件下,通过减少MMP-2分泌、降低MT1-MMP表达以及抑制Akt磷酸化发挥抗侵袭作用。需要使用体内模型进行进一步研究,以评估TAO作为抗侵袭剂的潜在作用。